Objectives: The purpose of this study was to investigate if KDIGO (Kidney Disease: Improving Global Outcomes) criteria could be a useful outcome predictor of cisplatin-induced acute kidney injury (CIA). Methods: In the period between January 2006 and December 2011, we identified Japanese patients who had been diagnosed with cancer and treated with cisplatin as a first-line chemotherapy at Nagoya University Hospital. The serum creatinine was used to define CIA and determine the KDIGO criteria of each patient after chemotherapy within 7 days. Results: Eighty-nine patients (5.4%) were classified as having acute kidney injury (AKI) going by the KDIGO criteria, and the numbers of patients classified into AKI stages 1, 2 and 3 were 65 (3.9%), 18 (1.1%) and 6 (0.4%), respectively. Overall survival times were significantly shorter in AKI stages 2 and 3 than in stage 1. The area under the receiver operating characteristic curve with all patients was 0.68, and that of patients who were diagnosed with cancer stage 4 was 0.80. Conclusion: These results suggest that KDIGO criteria can be a predictor of CIA mortality in patients with different primary cancers.

Keywords:
Acute kidney injury, Cisplatin, Kidney Disease: Improving Global Outcomes criteria, Serum creatinine
1.
Lamiere N, Van Biesen W, Vanholder R: Acute renal failure. Lancet 2005;365:417–430.
2.
Esson ML, Schrier RW: Diagnosis and treatment of acute tubular necrosis. Ann Intern Med 2002;137:744–752.
3.
Bellomo R, Ronco C, Kellum JA, et al: Acute renal failure definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:204–212.
4.
Mehta RL, Kellum JA, Shah SV, et al: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:31.
5.
Cruz DN, Bolgan I, Perazella MA, et al: North East Italian Prospective Hospital Renal Outcome Survey on Acute Kidney Injury (NEiPHROS-AKI): targeting the problem with the RIFLE criteria. Clin J Am Soc Nephrol 2007;2:418–425.
6.
Fonseca Ruiz NJ, Castro DP, Guerra AM, et al: Renal injury study in critical ill patients in accordance with the new definition given by the Acute Kidney Injury Network. J Crit Care 2011;26:206–212.
7.
Ho J, Reslerova M, Gali B, et al: Serum creatinine measurement immediately after cardiac surgery and prediction of acute kidney injury. Am J Kidney Dis 2012;59:196–201.
8.
Madias NE, Harrington JT: Platinium nephrotoxicity. Am J Med 1978;65:307–314.
9.
Goldstein RS, Mayor GH: Minireview: the nephrotoxicity of cisplatin. Life Sci 1983;32:685–690.
10.
Numico G, Benasso M, Vannozzi MO, et al: Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis. Anticancer Res 1998;18:1313–1318.
11.
Matsuo S, Imai E, Horio M, et al: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–992.
12.
Taguchi T, Nazneen A, Abid MR, Razzaque MS: Cisplatin associated nephrotoxicity and pathological events. Contrib Nephrol 2005;148:107–121.
13.
Arany I, Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460–464.
14.
Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M: Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 2008;61:903–909.
15.
Hsu CY, Ordonez JD, Chertow GM, et al: The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008;74:101–107.
16.
Chertow GM, Soroko SH, Paganini EP, et al: Mortality after acute renal failure: Models for prognostic stratification and risk adjustment. Kidney Int 2006;70:1120–1126.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.